Trial intelligence / Profile preview

CNI-free Myfortic + Certican versus standard CNI-based Myfortic regimen in stable renal transplant patients

2005-001013-18Phase 3Completed

Sponsor: Novartis
Start: Nov 2005
Modality: RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Peptides
Countries: 1

Overview

Phase 3, randomised, open-label trial of everolimus, mycophenolate sodium, cyclosporine and tacrolimus in kidney transplant (2 arms), sponsored by Novartis. Started Nov 2005; status: completed.

Drugs

everolimusmycophenolate sodiumcyclosporinetacrolimus

Conditions

kidney transplant

Beyond the preview

Go deeper on 2005-001013-18.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2005-001013-18.